<DOC>
	<DOCNO>NCT02000193</DOCNO>
	<brief_summary>This prospective , single arm phase II study evaluate efficacy safety fulvestrant maintenance hormone therapy first-line chemotherapy postmenopausal HR positive advance breast cancer .</brief_summary>
	<brief_title>Maintenance Hormone Therapy Postmenopausal HR Positive Advanced Breast Cancer</brief_title>
	<detailed_description>This prospective , single arm phase II study evaluate efficacy safety fulvestrant maintenance hormone therapy first-line chemotherapy postmenopausal HR positive advance breast cancer . Approximately 58 woman stable disease respond first line chemotherapy least 4 less 8 week treatment metastatic breast cancer enrol study receive fulvestrant 500mg maintenance therapy . The treatment continue objective disease progression intolerable AE . Efficacy determine base tumor assessment perform investigator accord RECIST ( Response Evaluation Criteria Solid Tumors ) 1.1 . Safety monitor base frequency severity adverse event ( AEs ) , assessed Common Terminology Criteria ( CTC ) grade version 4.0 . Tumor assessment assess compute tomography ( CT ) magnetic resonance imaging ( MRI ) every 12 week patient document evidence objective disease progression . Reporting SAEs ( serious adverse event ) regulatory authority do investigator accordance local regulation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Provision inform consent Histologically proven HR positive breast cancer Postmenopausal woman , define woman fulfil 1 follow criterion ( base NCCN definition menopause [ National Comprehensive Cancer Network 2008 ] ) : Prior bilateral oophorectomy Age â‰¥60 year Age &lt; 60 year amenorrheic 12 month absence chemotherapy , tamoxifen , toremifene , ovarian suppression follicle stimulate hormone oestradiol postmenopausal range . Patients complete firstline chemotherapy metastatic breast cancer The firstline chemotherapy must give patient visceral disease progressive disease require fast response Responded ( CR PR ) stabilize ( SD &gt; =24 week ) firstline chemotherapy metastatic breast cancer The duration 1st line chemotherapy advance breast cancer least 4 cycle 8 cycle WHO performance status 0 , 1 2 Presence lifethreatening metastatic visceral disease , define extensive hepatic involvement , degree brain leptomeningeal involvement ( past present ) Prior hormonal treatment metastatic breast cancer allow More one line cytotoxic chemotherapy metastatic breast cancer Her2 positive Other malignant tumor ( concurrent previous ) . Any severe concomitant condition make undesirable patient participate trial would jeopardise compliance study protocol , eg , uncontrolled cardiac disease uncontrolled diabetes mellitus</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>